uniQure Hemophilia B Deal With CSL Leaves M&A Fans Miffed

Dutch Group Gets $450m Upfront For Gene Therapy

Observers have been expecting uniQure to be sold off as a whole but the Netherlands-based firm has chosen to sell just one asset - EtranaDez - and focus on advancing its Huntington’s disease gene therapy.

Genetic breakthrough and medical gene therapy treatment discovery concept as a dart hitting a target by breaking a double helix representing genes as a 3D illustration.
CSL hopes hemophilia B gene therapy will hit the target • Source: Shutterstock

The likelihood of a uniQure NV buyout, regularly touted as a takeover target for big pharma, looks to have diminished after the Dutch firm plumped instead for a licensing agreement with blood plasma major CSL Behring for etranacogene dezaparvovec, its gene therapy for patients with hemophilia B.

The deal will see the Amsterdam-headquartered biotech bank a $450m upfront payment and it is eligible to receive up to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies